Results 231 to 240 of about 633,145 (289)

Gleaning the Rocky Shore? 2500 Years of Coastal Resource Use at Red Bluff 1, GunaiKurnai Country, SE Australia

open access: yesArchaeology in Oceania, EarlyView.
ABSTRACT Shell middens in Gippsland along the eastern half of Victoria's coastline have usually been characterised as small, short‐duration camp sites with relatively low shell densities and low taxonomic diversity. Here we present new excavation results from a dense, high‐diversity site at Red Bluff near the eastern end of GunaiKurnai Country, a ...
Patrick Faulkner   +17 more
wiley   +1 more source

Multi‐Method Geophysical Surveys Between and Around the Kerlescan and the Manio Megalithic Alignments in Carnac (Morbihan, France)

open access: yesArchaeological Prospection, EarlyView.
ABSTRACT The Carnac alignments in Morbihan (France) are among the most famous Neolithic sites of the world. Paradoxically, they have benefited little from a thorough renewal of archaeological data over the past century. There are many reasons for this, but it is mainly because the site has been regarded more as a monument to visit and protect than as ...
Guillaume Bruniaux   +6 more
wiley   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi   +12 more
wiley   +1 more source

Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of the Phase 3, Randomized, Placebo‐Controlled SOLSTICE Study

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Evaluate the efficacy and safety of guselkumab, an interleukin‐23p19‐subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor inhibitor (TNFi‐IR).
Alexis Ogdie   +12 more
wiley   +1 more source

Natural Disaster

open access: yesThe European Journal of Educational Sciences, 2019
openaire   +1 more source

Home - About - Disclaimer - Privacy